These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22014036)

  • 1. Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay.
    Laeyendecker O; Brookmeyer R; Oliver AE; Mullis CE; Eaton KP; Mueller AC; Jacobson LP; Margolick JB; Brown J; Rinaldo CR; Quinn TC; Eshleman SH;
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):816-22. PubMed ID: 22014036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries.
    Laeyendecker O; Brookmeyer R; Mullis CE; Donnell D; Lingappa J; Celum C; Baeten JM; Campbell MS; Essex M; de Bruyn G; Farquhar C; Quinn TC; Eshleman SH;
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1177-83. PubMed ID: 22283149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV incidence determination in the United States: a multiassay approach.
    Laeyendecker O; Brookmeyer R; Cousins MM; Mullis CE; Konikoff J; Donnell D; Celum C; Buchbinder SP; Seage GR; Kirk GD; Mehta SH; Astemborski J; Jacobson LP; Margolick JB; Brown J; Quinn TC; Eshleman SH
    J Infect Dis; 2013 Jan; 207(2):232-9. PubMed ID: 23129760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy.
    Marinda ET; Hargrove J; Preiser W; Slabbert H; van Zyl G; Levin J; Moulton LH; Welte A; Humphrey J
    J Acquir Immune Defic Syndr; 2010 Apr; 53(4):496-9. PubMed ID: 20306555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay.
    Longosz AF; Mehta SH; Kirk GD; Margolick JB; Brown J; Quinn TC; Eshleman SH; Laeyendecker O
    AIDS; 2014 May; 28(8):1227-32. PubMed ID: 24513567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A system review on the application of BED-capture enzyme immunoassay in detecting new HIV-1 infection].
    Tao J; Zhao J; Liu Y; Meng LZ; Yu SC; Jiang Y; Xiao Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Feb; 32(2):177-81. PubMed ID: 21518629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased specificity of an assay for recent infection in HIV-1-infected patients on highly active antiretroviral treatment: implications for incidence estimates.
    Chaillon A; Le Vu S; Brunet S; Gras G; Bastides F; Bernard L; Meyer L; Barin F
    Clin Vaccine Immunol; 2012 Aug; 19(8):1248-53. PubMed ID: 22718132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay.
    Hayashida T; Gatanaga H; Tanuma J; Oka S
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):495-8. PubMed ID: 18327979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the bio-rad avidity assay, and the BED capture immunoassay in Rakai, Uganda.
    Longosz AF; Serwadda D; Nalugoda F; Kigozi G; Franco V; Gray RH; Quinn TC; Eshleman SH; Laeyendecker O
    AIDS Res Hum Retroviruses; 2014 Apr; 30(4):339-44. PubMed ID: 24083837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating False-Recent Classification for the Limiting-Antigen Avidity EIA and BED-Capture Enzyme Immunoassay in Vietnam: Implications for HIV-1 Incidence Estimates.
    Shah NS; Duong YT; Le LV; Tuan NA; Parekh BS; Ha HTT; Pham QD; Cuc CTT; Dobbs T; Tram TH; Lien TTX; Wagar N; Yang C; Martin A; Wolfe M; Hien NT; Kim AA
    AIDS Res Hum Retroviruses; 2017 Jun; 33(6):546-554. PubMed ID: 28193090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential specificity of HIV incidence assays in HIV subtypes A and D-infected individuals from Rakai, Uganda.
    Mullis CE; Munshaw S; Grabowski MK; Eshleman SH; Serwadda D; Brookmeyer R; Nalugoda F; Kigozi G; Kagaayi J; Tobian AA; Wawer M; Gray RH; Quinn TC; Laeyendecker O
    AIDS Res Hum Retroviruses; 2013 Aug; 29(8):1146-50. PubMed ID: 23641870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa.
    Karita E; Price M; Hunter E; Chomba E; Allen S; Fei L; Kamali A; Sanders EJ; Anzala O; Katende M; Ketter N;
    AIDS; 2007 Feb; 21(4):403-8. PubMed ID: 17301558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved testing of recent HIV-1 infections with the BioRad avidity assay compared to the limiting antigen avidity assay and BED Capture enzyme immunoassay: evaluation using reference sample panels from the German Seroconverter Cohort.
    Hauser A; Santos-Hoevener C; Meixenberger K; Zimmermann R; Somogyi S; Fiedler S; Hofmann A; Bartmeyer B; Jansen K; Hamouda O; Bannert N; Kuecherer C
    PLoS One; 2014; 9(6):e98038. PubMed ID: 24892795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to highly active antiretroviral therapy according to duration of HIV infection.
    Pezzotti P; Pappagallo M; Phillips AN; Boros S; Valdarchi C; Sinicco A; Zaccarelli M; Rezza G;
    J Acquir Immune Defic Syndr; 2001 Apr; 26(5):473-9. PubMed ID: 11391168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection.
    Wendel SK; Mullis CE; Eshleman SH; Blankson JN; Moore RD; Keruly JC; Brookmeyer R; Quinn TC; Laeyendecker O
    PLoS One; 2013; 8(2):e55525. PubMed ID: 23437058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States.
    Konikoff J; Brookmeyer R; Longosz AF; Cousins MM; Celum C; Buchbinder SP; Seage GR; Kirk GD; Moore RD; Mehta SH; Margolick JB; Brown J; Mayer KH; Koblin BA; Justman JE; Hodder SL; Quinn TC; Eshleman SH; Laeyendecker O
    PLoS One; 2013; 8(12):e82772. PubMed ID: 24386116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations.
    Kirkpatrick AR; Patel EU; Celum CL; Moore RD; Blankson JN; Mehta SH; Kirk GD; Margolick JB; Quinn TC; Eshleman SH; Laeyendecker O
    AIDS Res Hum Retroviruses; 2016 Aug; 32(8):756-62. PubMed ID: 26988426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay.
    Longosz AF; Morrison CS; Chen PL; Arts E; Nankya I; Salata RA; Franco V; Quinn TC; Eshleman SH; Laeyendecker O
    J Acquir Immune Defic Syndr; 2014 Apr; 65(4):390-6. PubMed ID: 24583613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.